Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial – The Lancet

CTH522 adjuvanted with either CAF01 or aluminium hydroxide appears to be safe and
well tolerated. Both vaccines were immunogenic, although CTH522:CAF01 had a better
immunogenicity profile, holding promise for further clinical development.
Read More

LEAVE REPLY

Your email address will not be published. Required fields are marked *